Human C-Reactive Protein (CRP) FlowCytomix Simplex

Description: This FlowCytomix Simplex Kit is designed for the measurement of Human CRP in an immunoassay analyzed on a flow cytometer. Together with the FlowCytomix Human Basic Kit (cat. BMS8420FF), this kit can be used to detect CRP alone or can be multiplexed with other Simplex Kits to measure a variety of analytes.

This kit contains bead population A9.

C-reactive protein is an acute phase protein exclusively synthesized by hepatocytes in response to cytokines released into circulation by activated leukocytes. Serum and plasma levels of CRP have been shown to rise during response to a wide variety of diseases including bacterial infections, acute phase of rheumatoid arthritis, inflammation of the bile duct. High CRP is also found in Guillain-Barre syndrome patients, in multiple sclerosis, viral infections, tuberculosis, acute infectious hepatitis, necrotic diseases, burned patients and after surgical trauma.

CRP thus has been shown to be a useful indicator of inflammatory processes. CRP levels rise in serum or plasma within 24 to 48 hours after acute tissue damage, peaking at acute stage and decreasing with resolution of inflammation or trauma. In addition to being a marker of inflammatory diseases, CRP turned out to be a predictive value as cardiac marker to assess risk of cardio vascular and peripheral vascular disease.

References: van Leeuwen,M.A.; van Rijswijk,M.H.. Acute phase proteins in the monitoring of inflammatory disorders. Baillieres Clin.Rheumatol. 1994;8:531-552. (Link)

Macy,E.M.; Hayes,T.E.; Tracy,R.P.. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin.Chem. 1997;43:52-58. (Link)

Uotila,M.; Ruoslahti,E.; Engvall,E.. Two-site sandwich enzyme immunoassay with monoclonal antibodies to human alpha-fetoprotein. J.Immunol.Methods 1981;42:11-15. (Link)

Lee,S.H.; Brennan,F.R.; Jacobs,J.J.; Urban,R.M.; Ragasa,D.R.; Glant,T.T.. Human monocyte/macrophage response to cobalt-chromium corrosion products and titanium particles in patients with total joint replacements. J.Orthop.Res. 1997;15:40-49. (Link)

Morley,J.J.; Kushner,I.. Serum C-reactive protein levels in disease. Ann.N.Y.Acad.Sci. 1982;389:406-418. (Link)

Ridker,P.M.; Glynn,R.J.; Hennekens,C.H.. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011. (Link)

Kushner,I.; Rzewnicki,D.L.. The acute phase response: general aspects. Baillieres Clin.Rheumatol. 1994;8:513-530. (Link)

Shine,B.; de Beer,F.C.; Pepys,M.B.. Solid phase radioimmunoassays for human C-reactive protein. Clin.Chim.Acta 1981;117:13-23. (Link)

Morley,J.J.; Kushner,I.. Serum C-reactive protein levels in disease. Ann.N Y.Acad.Sci. 1982;389:406-418. (Link)

Kushner,I.. C-reactive protein in rheumatology. Arthritis Rheum. 1991;34:1065-1068. (Link)

Schultz,D.R.; Arnold,P.I.. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin.Arthritis Rheum. 1990;20:129-147. (Link)

Tracy,R.P.; Lemaitre,R.N.; Psaty,B.M.; Ives,D.G.; Evans,R.W.; Cushman,M.; Meilahn,E.N.; Kuller,L.H.. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler.Thromb.Vasc.Biol. 1997;17:1121-1127. (Link)